Alnylam Pharmaceuticals, Inc. (ALNY)
155.94
-0.72
(-0.46%)
USD |
NASDAQ |
Nov 06, 16:00
156.25
+0.31
(+0.20%)
After-Hours: 20:00
Alnylam Pharmaceuticals Free Cash Flow : 752.13M for Sept. 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2026 | 752.13M |
| June 30, 2026 | 765.69M |
| March 31, 2026 | 589.16M |
| December 31, 2025 | 411.21M |
| September 30, 2025 | 167.19M |
| June 30, 2025 | -78.01M |
| March 31, 2025 | -77.38M |
| December 31, 2024 | -42.59M |
| September 30, 2024 | 16.06M |
| June 30, 2024 | 318.87M |
| March 31, 2024 | 127.82M |
| December 31, 2023 | 41.94M |
| September 30, 2023 | -66.56M |
| June 30, 2023 | -540.68M |
| March 31, 2023 | -604.65M |
| December 31, 2022 | -613.33M |
| September 30, 2022 | -631.75M |
| June 30, 2022 | -660.05M |
| March 31, 2022 | -654.28M |
| December 31, 2021 | -718.06M |
| September 30, 2021 | -690.85M |
| June 30, 2021 | -653.50M |
| March 31, 2021 | -672.38M |
| December 31, 2020 | -685.32M |
| September 30, 2020 | -775.30M |
| Date | Value |
|---|---|
| June 30, 2020 | -871.24M |
| March 31, 2020 | -451.80M |
| December 31, 2019 | -418.58M |
| September 30, 2019 | -371.77M |
| June 30, 2019 | -352.30M |
| March 31, 2019 | -745.14M |
| December 31, 2018 | -689.50M |
| September 30, 2018 | -625.30M |
| June 30, 2018 | -550.13M |
| March 31, 2018 | -527.43M |
| December 31, 2017 | -487.00M |
| September 30, 2017 | -461.44M |
| June 30, 2017 | -433.23M |
| March 31, 2017 | -413.30M |
| December 31, 2016 | -372.26M |
| September 30, 2016 | -330.20M |
| June 30, 2016 | -295.21M |
| March 31, 2016 | -269.16M |
| December 31, 2015 | -202.09M |
| September 30, 2015 | -186.09M |
| June 30, 2015 | -169.15M |
| March 31, 2015 | -160.90M |
| December 31, 2014 | -174.60M |
| September 30, 2014 | -157.69M |
| June 30, 2014 | -136.45M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Ionis Pharmaceuticals, Inc. | -567.50M |
| Vertex Pharmaceuticals, Inc. | 3.202B |
| Pfizer Inc. | 11.79B |
| BridgeBio Pharma, Inc. | -369.80M |
| Cerenome, Inc. | -23.55M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 340.98M |
| Cash from Investing (Quarterly) | -311.74M |
| Cash from Financing (Quarterly) | 18.35M |
| Free Cash Flow Per Share (Quarterly) | 1.964 |
| Free Cash Flow to Equity (Quarterly) | 261.78M |
| Free Cash Flow to Firm (Quarterly) | 889.33M |
| Free Cash Flow Yield | 3.50% |